The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 32, No. 10, pp. 1060-1066. DOI 10.1345/aph.17388
© 1998 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pylypchuk, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pylypchuk, G.


Research Articles

ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema

GB Pylypchuk

OBJECTIVE: To compare the tolerability of angiotensin-converting enzyme (ACE) inhibitors with that of angiotensin II (AII)-receptor blockers and the incidence of cough and angioedema associated with their use through review of published data. DATA SOURCES: References were identified through a MEDLINE search of articles published between January 1975 and April 1997. Bibliographies of pertinent references were also reviewed. RESULTS: Results of placebo-controlled and comparative trials of the AII blockers demonstrate that they are at least as effective as ACE inhibitors for hypertension, but exhibit an incidence of cough and absent or rare angioedema like that of placebo. CONCLUSIONS: In the 10 comparative trials described, all reported a lower incidence of cough with AII blockers than with ACE inhibitors. Angioedema was not reported in the comparative trials described.


This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
G. Nickenig, J. Ostergren, and H. Struijker-Boudier
Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Journal of Renin-Angiotensin-Aldosterone System, March 1, 2006; 7(1_suppl): S1 - S7.
[Abstract] [PDF]


Home page
ChestHome page
P. V. Dicpinigaitis
Angiotensin-Converting Enzyme Inhibitor-Induced Cough: ACCP Evidence-Based Clinical Practice Guidelines
Chest, January 1, 2006; 129(1_suppl): 169S - 173S.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
B. K Irons and A. Kumar
Valsartan-Induced Angioedema
Ann. Pharmacother., July 1, 2003; 37(7): 1024 - 1027.
[Abstract] [Full Text] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
M. A Weber
Review: Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
Journal of Renin-Angiotensin-Aldosterone System, June 1, 2003; 4(2): 62 - 73.
[Abstract] [PDF]


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
D. A Sica and T. W. Gehr
Review: The pharmacokinetics and pharmacodynamics of angiotensin-receptor blockers in end-stage renal disease
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 247 - 254.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
S. P. Marso
Optimizing the diabetic formulary: beyond aspirin and insulin
J. Am. Coll. Cardiol., August 21, 2002; 40(4): 652 - 661.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
P. C. Deedwania
Hypertension and Diabetes: New Therapeutic Options
Arch Intern Med, June 12, 2000; 160(11): 1585 - 1594.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1998 by Harvey Whitney Books Company.